SEC Form SC 13G/A filed by Intersect ENT, Inc. (Amendment)

9/10/21 9:33:54 AM ET

Medical/Dental Instruments

Health Care

Get the next $XENT alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 2 INTERSECT ENT INC COMMON STOCK Cusip #46071F103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #46071F103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000% Item 12: HC Cusip #46071F103 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000% Item 12: IN Item 1(a). Name of Issuer: INTERSECT ENT INC Item 1(b). Address of Issuer's Principal Executive Offices: 1555 ADAMS DRIVE MENLO PARK, CA 94025 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 46071F103 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 0 (b) Percent of Class: 0.000% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of any of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. September 9, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on September 9, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of INTERSECT ENT INC at August 31, 2021. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $XENT alert in real time by email

Date

Price Target

Rating

Analyst

8/12/2021

$28.25

Outperform → Market Perform

SVB Leerink

8/10/2021

Buy → Neutral

BTIG

8/9/2021

$29.00 → $28.25

Buy → Hold

Canaccord Genuity

8/9/2021

$28.25

Buy → Neutral

Guggenheim

6/24/2021

$21.00 → $23.00

Market Perform → Outperform

SVB Leerink

SEC Form SC 13G/A filed by Intersect ENT, Inc. (Amendment)

9/10/21 9:33:54 AM ET

$XENT

Medical/Dental Instruments

Health Care

Get the next $XENT alert in real time by email

Date

Price Target

Rating

Analyst

8/12/2021

$28.25

Outperform → Market Perform

SVB Leerink

8/10/2021

Buy → Neutral

BTIG

8/9/2021

$29.00 → $28.25

Buy → Hold

Canaccord Genuity

8/9/2021

$28.25

Buy → Neutral

Guggenheim

6/24/2021

$21.00 → $23.00

Market Perform → Outperform

SVB Leerink

SEC Form SC 13G/A filed by Intersect ENT, Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$XENT

SEC Form SC 13G/A filed by Intersect ENT, Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$XENT

$XENT
FDA approvals

FDA Approval for SINUVA issued to INTERSECT ENT INC

$XENT
Press Releases

Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer

Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Orthofix Announces Appointment of Thomas A. West to Board of Directors

$XENT
Analyst Ratings

Intersect ENT downgraded by SVB Leerink with a new price target

Intersect ENT downgraded by BTIG

Intersect ENT downgraded by Canaccord Genuity with a new price target

$XENT
SEC Filings

SEC Form POSASR filed by Intersect ENT Inc.

SEC Form RW WD filed by Intersect ENT Inc.

SEC Form 15-12B filed by Intersect ENT Inc.

$XENT
Insider Trading

SEC Form 4 filed by Hattangadi Neil A

SEC Form 4: Meier Richard A closing all direct ownership in the company

SEC Form 4: Fernandez Reyna M closing all direct ownership in the company

$XENT
Leadership Updates

Orthofix Announces Appointment of Thomas A. West to Board of Directors

Intersect ENT Announces Appointment of New Vice President of Sales

$XENT
Large Ownership Changes